About Genomic Health
Genomic Health, Inc. is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer. Its Oncotype DX tests utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction, in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. It offers its services and products, including Oncotype DX Breast Cancer Test, Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test through its Oncotype IQ Genomic Intelligence Platform.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Laboratories & Research
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: GHDX
- CUSIP: 37244C10
- Previous Close: $29.53
- 50 Day Moving Average: $28.22
- 200 Day Moving Average: $29.13
- 52-Week Range: $22.00 - $33.96
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 84.37
- P/E Growth: 174.55
- Market Cap: $993.06M
- Outstanding Shares: 33,629,000
- Beta: 0.46
- Net Margins: -5.77%
- Return on Equity: -14.13%
- Return on Assets: -10.77%
Companies Related to Genomic Health:
- Current Ratio: 3.28%
- Quick Ratio: 3.28%
What is Genomic Health's stock symbol?
Genomic Health trades on the NASDAQ under the ticker symbol "GHDX."
Where is Genomic Health's stock going? Where will Genomic Health's stock price be in 2017?
7 brokerages have issued 12-month price targets for Genomic Health's shares. Their forecasts range from $27.00 to $38.00. On average, they anticipate Genomic Health's stock price to reach $30.83 in the next year.
When will Genomic Health announce their earnings?
Genomic Health is scheduled to release their next quarterly earnings announcement on Tuesday, May, 2nd 2017.
Who owns Genomic Health stock?
Genomic Health's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Columbia Wanger Asset Management LLC (3.81%), Renaissance Technologies LLC (1.72%), State Street Corp (1.63%), Loomis Sayles & Co. L P (1.59%), FMR LLC (0.79%) and Two Sigma Investments LP (0.61%). Company insiders that own Genomic Health stock include Felix Baker, G Bradley Cole, James J Vaughn, Kimberly J Popovits, Phillip G Febbo, Randall S Livingston and Steven Shak.
Who sold Genomic Health stock? Who is selling Genomic Health stock?
Genomic Health's stock was sold by a variety of institutional investors in the last quarter, including Numeric Investors LLC, FMR LLC, Loomis Sayles & Co. L P, GSA Capital Partners LLP, Two Sigma Investments LP, AQR Capital Management LLC and Envestnet Asset Management Inc.. Company insiders that have sold Genomic Health stock in the last year include G Bradley Cole, James J Vaughn, Kimberly J Popovits, Phillip G Febbo and Steven Shak.
Who bought Genomic Health stock? Who is buying Genomic Health stock?
Genomic Health's stock was acquired by a variety of institutional investors in the last quarter, including Columbia Wanger Asset Management LLC, State Street Corp, Bogle Investment Management L P DE, Renaissance Technologies LLC, A.R.T. Advisors LLC, Aveo Capital Partners LLC, Russell Investments Group Ltd. and Capstone Investment Advisors LLC.
How do I buy Genomic Health stock?
Shares of Genomic Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Genomic Health stock cost?
One share of Genomic Health stock can currently be purchased for approximately $29.53.